NRAS and cancer: Although the sample sizes for patients with NRAS mutation in LAML and LUAD are too small (n = 11 or 10, respectively) and that could lead to statistical bias, it is still encouraging to see the survival difference, supporting our hypothesis that miR-708 can serve as a therapeutic option in treating NRAS mutation-driven cancers.